Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register

Frisell Thomas; Dehlin Mats; Di Giuseppe Daniela; Feltelius Nils; Turesson Carl; Askling Johan; Ernestam Sofia; Klareskog Lars; Nisell Ralph; Baecklund Eva; Kastbom Alf; Jacobsson Lennart; Lindqvist Elisabet; dElia Helena Forsblad; Rantapaa-Dahlqvist Solbritt

首页> 外文期刊>Rheumatology >Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register

【24h】

Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register

机译：AbataCept，Rituximab，Tocolizumab和TNFI生物学在RA的比较有效性：全国瑞典登记册的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objectives. Current guidelines rank abatacept, rituximab, tocilizumab and TNF-inhibitors (TNFi) as having equal effectiveness for the treatment of RA, at least as second line therapies. These recommendations are mainly based on meta-analysis of randomized controlled trials, with few direct drug-drug comparisons. Our objective was to compare the real-world absolute and relative effectiveness among RA patients starting any of the available biologic DMARDs (bDMARDs).

机译：目标。目前的指南排名Abatacept，Rituximab，Toc抑制剂（TNFI），其具有相同的效果来治疗RA，至少作为第二线疗法。这些建议主要基于对随机对照试验的荟萃分析，具有少量直接药物 - 药物比较。我们的目标是将RA患者的现实世界绝对和相对有效性进行比较，从任何可用的生物学DMARD（BDMARDS）开始。

著录项

来源
《Rheumatology》 |2019年第8期|共11页
作者
Frisell Thomas; Dehlin Mats; Di Giuseppe Daniela; Feltelius Nils; Turesson Carl; Askling Johan; Ernestam Sofia; Klareskog Lars; Nisell Ralph; Baecklund Eva; Kastbom Alf; Jacobsson Lennart; Lindqvist Elisabet; dElia Helena Forsblad; Rantapaa-Dahlqvist Solbritt;
展开▼
作者单位

Karolinska Inst Dept Med Solna Div Clin Epidemiol Stockholm Sweden;

Univ Gothenburg Sahlgrenska Acad Dept Rheumatol &

Inflammat Res Gothenburg Sweden;

Karolinska Inst Dept Med Solna Div Clin Epidemiol Stockholm Sweden;

Med Prod Agcy Uppsala Sweden;

Lund Univ Dept Clin Sci Rheumatol Malmo Sweden;

Karolinska Inst Dept Med Solna Div Clin Epidemiol Stockholm Sweden;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词
rheumatoid arthritis; effectiveness; treatment outcome; biologics; anti-TNF; rituximab; abatacept; tocilizumab;

机译：类风湿性关节炎;有效性;治疗结果;生物学;抗TNF;rituximab;abatacept;tocilizumab;

相似文献

外文文献
中文文献
专利

1. Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply [J] . Frisell Thomas, Askling Johan Rheumatology . 2019,第8期

机译：评论：Abatacept，Rituximab，Tocilizumab和TNFI生物学在RA的比较效果：全国瑞典寄存器的结果：答复
2. Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from a nationwide Swedish register [J] . Weil Andrew N. B. Rheumatology . 2019,第8期

机译：评论：ABATACEPT，RITUXIMAB，TOCHIZUMAB和TNFI生物学在RA的比较效果：全国瑞典登记册的结果
3. Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply [J] . Frisell Thomas, Askling Johan Rheumatology . 2019,第8期

机译：评论：Abatacept，Rituximab，Tocilizumab和TNFI生物学在RA的比较效果：全国瑞典寄存器的结果：答复
4. The biological CTLA4lg (Abatacept) reduces CD28~(null) T-cells in Rheumatoid Arthritis (RA) [C] . Hebel Katrin, Knieke Karin, Hirseland Heike, European Congress of Immunology . 2009

机译：生物CTLA4Lg（Abatacept）减少了类风湿性关节炎（RA）中的CD28〜（零）T细胞
5. Education Level and Critical Thinking Skills Among Substance Use Counselors Nationwide: A Descriptive Comparative Study [D] . Eakman, Teresa L. 2017

机译：全国物质使用顾问的教育水平和批判性思维技巧：描述性比较研究
6. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry [O] . Leslie R. Harrold, George W. Reed, Daniel H. Solomon, 2016

机译：在美国Corrona注册中心中有TNFi暴露的类风湿关节炎患者中abatacept与tocilizumab的比较有效性
7. Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply [O] . Thomas Frisell, Johan Askling 2019

机译：评论：AbataCept，Rituximab，Tocolizumab和TNFI生物学在RA的比较效果：全国瑞典寄存器的结果：答复

Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register

摘要

著录项

相似文献

相关主题

期刊订阅